<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B141CC2-09C5-4864-86B5-A9CAEBCF2531"><gtr:id>7B141CC2-09C5-4864-86B5-A9CAEBCF2531</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>FRANCIS</gtr:otherNames><gtr:surname>Marshall</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC41B47B-F486-48E0-9038-EFBBBEDC8DD3"><gtr:id>EC41B47B-F486-48E0-9038-EFBBBEDC8DD3</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Barry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C79947BC-9401-4977-8C25-7864419FDA92"><gtr:id>C79947BC-9401-4977-8C25-7864419FDA92</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Roger</gtr:otherNames><gtr:surname>Hart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7F5B347F-6DC2-4C30-AD1B-23E877D5BB59"><gtr:id>7F5B347F-6DC2-4C30-AD1B-23E877D5BB59</gtr:id><gtr:firstName>Gareth</gtr:firstName><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800825"><gtr:id>B32510A2-671F-46DF-9ED4-9051B81E57E9</gtr:id><gtr:title>Establishing the utility and molecular mechanisms of integrin alphav beta6-directed human-antibody therapy of cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800825</gtr:grantReference><gtr:abstractText>The ability of cancers to invade requires that they have certain specialised molecules on their surface and it is this invasive ability that allows cancers to spread around the body and ultimately kill people. We have identified a new invasion-promoting molecule called alphav beta6. It is on the surface of many different types of cancer and our analysis of cancer tissues taken from patients who have died from the disease, show that the presence of alphav beta6 on cancers can significantly shorten life-expectancy. We believe by preventing alphav beta6 from working we can slow down or even stop cancers from invading and, therefore, from killing people so quickly. In this proposal, using our specialised experimental systems, we will test the ability of antibodies, designed to stop alphav beta6 from working properly, to actually prevent the growth and invasion of cancers. We expect that our studies will allow us to treat cancer patients with these antibodies in the near future. Our study will also investigate how the alphav beta6 actually changes the behaviour of cancers to enable them to invade. This information will allow us to create even better therapies for cancer in the future.</gtr:abstractText><gtr:technicalSummary>The epithelial-specific integrin, alphav beta6, is weak or absent on normal adult tissues but is upregulated on many carcinomas where its strong expression correlates with poor prognosis for those with cancers of the colon, cervix, lung and breast. Our data offer an experimental explanation for these observations. We were the first to show that alphav beta6 promotes invasion of Matrigel in vitro, in a MMP9/plasmin-dependent manner and that antibodies which blocked ligand-binding to alphav beta6 abrogated this invasion. More recently, using organotypic cultures that better replicate the real tumour environment, as they are a composition of cancer cells overlying a stromal collagen matrix embedded with fibroblasts, we confirmed by transplanting organotypic gels into mice, that alphav beta6 also promotes carcinoma invasion in vivo, although the mechanisms remain obscure. Since alphav beta6 is not highly expressed on normal tissues blockade of alphav beta6 ligand-binding is likely to be an effective and safe therapy for the treatment of alphav beta6-positive cancers. Astra Zeneca have generated novel human antibodies that specifically inhibit the ability of alphav beta6 to bind to its ligands (including fibronectin and the latency associated peptide {LAP} of TGFbeta). In this study, using these organotypic gels, we shall confirm that these novel alphav beta6-blocking human antibodies can suppress alphav beta6-dependent carcinoma invasion and growth in vitro and in vivo, as a prelude to their use for the alphav beta6-directed therapy of cancers in humans. We shall also determine the molecular mechanisms of alphav beta6-promoted invasion and growth. It is likely that 1) promotion of increased secretion of proteases, 2) activation of TGFbeta and thus activation of stromal fibroblasts or 3) a combination of both mechanisms, explain why alphav beta6 is such an aggressive component of carcinoma development. Thus we shall generate organotypic gels with carcinoma cell lines (eg VB6, BICR6, CA1) that exhibit alphav beta6-dependent invasion, together with human foetal foreskin fibroblast 2 (HFFF2) cells, where one or both cellular components have been treated with siRNAi to selectively knockdown expression of individual key targets (including MMP9, uPAR, TGFbeta, TGFbeta-receptor). Once the principal pathways of alphav beta6-dependent invasion have been identified in vitro, we shall use shRNA to generate stable variant carcinoma and fibroblast lines, to generate organotypic gels for transplanting into mice and thus confirm the mechanisms in vivo. These studies will confirm that we have effective therapeutic anti-alphav beta6 antibodies and establish their mechanism of action.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-18</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>317076</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Investigate the role of antibody 264RAD as a therapeutic in cancer</gtr:description><gtr:id>56F24CFD-26AC-4ACA-A1DB-91C95AF2294B</gtr:id><gtr:impact>Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AG, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL* and Marshall JF*. Therapeutic targeting of integrin av?6 in breast cancer. J Natl Cancer Inst 2014 106(8). pii: dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug</gtr:impact><gtr:outcomeId>J8mfQ8ssjcy-1</gtr:outcomeId><gtr:partnerContribution>Supply of 264RAD without cost.
Supply of knowhow (methodologies) for experiments that AZ have optimised.
Supply of AZ drugs for key experiments
Supply of animals for in vivo studies</gtr:partnerContribution><gtr:piContribution>We have conducted experiments with 264RAD, an antibody that inhibits the activity of integrins alphav beta6 and alphav beta8. These pre-clinical experiments have led to application to Cancer Research UK for funding a phase I trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Pint of Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FAFBB54E-0F4F-40E6-B889-C254B85583C8</gtr:id><gtr:impact>Pint of Science is bringing science to the public by giving talks in pubs. My talk was 18th May 2015 and entitled &amp;quot;How Cows can help Cure cancer&amp;quot;</gtr:impact><gtr:outcomeId>56dd700d9aa3e2.90721429</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://pintofscience.com</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker at Fibronectin, Integrin Gordon Conference, Ventura, USA, Jan 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6BF3E769-F924-472B-A8F3-75BAD085115E</gtr:id><gtr:impact>This bi-annual conference brings scientists from across the world to discuss integrins. I was invited to speak on the translational aspects of targeting integrin alpha-v beta-6</gtr:impact><gtr:outcomeId>58b5ac46ef8450.56889070</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Annual Race for Life</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3725C165-C023-4291-A24B-EC924BDE2C19</gtr:id><gtr:impact>Guest speaker at the CRUK Annual Relay for Life Supporters Event, held November 14th at a hotel in Heathrow.
This was an event to celebrate the work of fund raisers in the previous year. There were about 250 people present. The talk resulted in a standing ovation so I think it was well received.</gtr:impact><gtr:outcomeId>56dd6f4871fa35.04967129</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Barts Cancer Centre event for mid-value supporters</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E12945AE-25E8-4FA3-AEE6-E9DF2E7344AE</gtr:id><gtr:impact>Two separate cohorts of supporters/fund raisers for CRUK visited Barts Cancer institute Feb 15th 2017. I gave a seminar to each cohort. The goal was to enthuse, inspire and encourage the supporters that their efforts were warmly received but also valuable and having an effect on research.</gtr:impact><gtr:outcomeId>58b5a47b3fa504.40473433</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Supporters Visit 011215</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FAF21962-A6E1-47FA-8EFB-9F4BF580A30C</gtr:id><gtr:impact>CRUK arrange visits for supporters to my institute. I regularly host these visits and provides science talks on what we do and hope to achieve.</gtr:impact><gtr:outcomeId>56dd70c7c45103.33785987</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Supporters visit November 15th 2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>86078B97-022C-4815-AD6C-A07BB1857305</gtr:id><gtr:impact>We showed the research we do at BCI to a group of visitors. We discussed technology development and costs required. We showed live cancer cells down microscopes and also cancer material stained to reveal specific cells. The audience were engaged and asking questions about research progress in cancer.</gtr:impact><gtr:outcomeId>58b5a8377e3275.11348749</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Super Supporter Sept 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF9F29F6-562B-4E0C-B50E-14FBADD90F25</gtr:id><gtr:impact>A CRUK event on a Saturday for high value fund-raising groups. I spoke on our science and how they were collaborators in that task.</gtr:impact><gtr:outcomeId>56dd716bea0975.26513272</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of high throughput 3D invasion assays</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>E61E07A0-56DE-4EFC-B00E-C0E4B52B6FBC</gtr:id><gtr:outcomeId>56dd5e5fdcd4c7.40732182</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>219000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novel transgenic mouse models for identifying biomarkers of av?6/HER2-dependent breast cancer</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:fundingRef>2011NovPR47</gtr:fundingRef><gtr:id>E1729C78-4A2F-43E9-AD14-B3B25940F385</gtr:id><gtr:outcomeId>56dd5d1b49f3e2.20944365</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Preclinical development &amp;amp; CRUKD/17/002 a First-in-Man Phase I trial of 264RAD, a therapeutic antibody targeting of integrin alphav&amp;szlig;6 in Pancreatic Ductal Adenocarcinoma</gtr:description><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>17764</gtr:fundingRef><gtr:id>06DB370C-C070-4AF4-BA6D-80F4E8D0FAC6</gtr:id><gtr:outcomeId>56dd97f69023b2.05015706</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:id>89F701E0-5AF9-497D-A610-8EA60C35A79A</gtr:id><gtr:outcomeId>hZvmySB6CDT0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>264RAD is an antibody that we help to develop in collaboration with AstraZeneca Medimmune using an MRC grant.
These studies have led to a CRUK sponsored and funded phase I traial that is in development.
The antibodies are being manfactured at present. Regulatory paperwork (REC etc) have yet to be finalised and submitted for approval.

CRUK are funding the whole trial</gtr:description><gtr:id>4CD39F93-4A30-4B3F-8447-4FB1FBED6DCC</gtr:id><gtr:impact>We are making progress in development of blood-borne biomarkers for avb6-targeted therapy.</gtr:impact><gtr:outcomeId>56dd7b410dcd59.17807128</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>264RAD Antibody therapy of pancreas and breast cancer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have miniaturised our 3D invasion assay systen so that it requires less than 10% of the cell lines and extracellular matrix proteins and can be completed within 7d instead of 14d.</gtr:description><gtr:id>8E3E9668-42EC-4B28-B2BD-A62CFBFAB33C</gtr:id><gtr:impact>The miniaturisation allows us to look more efficiently at siRNA mediated gene knockout in complext 3D invasion assays</gtr:impact><gtr:outcomeId>HTh1Hu9Hkyz</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mini-organotypic invasion assays</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5D9BEC4E-7967-4B99-877B-E616F891486B</gtr:id><gtr:title>Suppression of TGF? and Angiogenesis by Type VII Collagen in Cutaneous SCC.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5baf1744c4fe9fa5a0a94e258f4d9143"><gtr:id>5baf1744c4fe9fa5a0a94e258f4d9143</gtr:id><gtr:otherNames>Martins VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>5aa12e3ba8c212.96984913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7BCAC5F-4619-47E9-8566-95B37A3E06DF</gtr:id><gtr:title>Integrins as Therapeutic Targets: Successes and Cancers.</gtr:title><gtr:parentPublicationTitle>Cancers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75923640a8fc13253cd7848ae4d5dd9e"><gtr:id>75923640a8fc13253cd7848ae4d5dd9e</gtr:id><gtr:otherNames>Raab-Westphal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2072-6694</gtr:issn><gtr:outcomeId>5aa12d6db61bf7.27204947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4106CDA4-F980-40B7-BAC7-EC82101433D3</gtr:id><gtr:title>Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b412716805ecf53b0cdd38f866a578b"><gtr:id>9b412716805ecf53b0cdd38f866a578b</gtr:id><gtr:otherNames>Hung KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>5aa12c4470b2d6.08027008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C676FA9-6B3C-4D65-BFB0-400CB4BC343E</gtr:id><gtr:title>The role of integrins in TGF? activation in the tumour stroma.</gtr:title><gtr:parentPublicationTitle>Cell and tissue research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0d7b7194499ab8d0916e4b4e92c01fb"><gtr:id>f0d7b7194499ab8d0916e4b4e92c01fb</gtr:id><gtr:otherNames>Khan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-766X</gtr:issn><gtr:outcomeId>5aa12dca638274.18692225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC28C0EC-E646-4200-B802-A8962EA71278</gtr:id><gtr:title>Therapeutic targeting of integrin av?6 in breast cancer.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68f7f1f7d91edac2a529b5381eebbf44"><gtr:id>68f7f1f7d91edac2a529b5381eebbf44</gtr:id><gtr:otherNames>Moore KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_540e160e160325095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F260C59-2194-4E17-8F8C-9B9928F3FF5F</gtr:id><gtr:title>A human monoclonal antibody 264RAD targeting av?6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca38894a6c7e71c95b8055d6611e4524"><gtr:id>ca38894a6c7e71c95b8055d6611e4524</gtr:id><gtr:otherNames>Eberlein C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_14960_20_23108397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E02D795-B50F-43E3-A203-885C78C285C3</gtr:id><gtr:title>Stromal features are predictive of disease mortality in oral cancer patients.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6013ae0bb85afc72b543ef2b3fae9394"><gtr:id>6013ae0bb85afc72b543ef2b3fae9394</gtr:id><gtr:otherNames>Marsh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_14960_20_21294121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44879862-4EA7-41EC-A41A-15D8F0536B1C</gtr:id><gtr:title>Targeting of Aberrant av?6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26df6ecbbfa25d74e3babc1f779db156"><gtr:id>26df6ecbbfa25d74e3babc1f779db156</gtr:id><gtr:otherNames>Whilding LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5aa12d429f9961.65586160</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800825</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>